Pharvaris (NASDAQ:PHVS) Announces Earnings Results

Pharvaris (NASDAQ:PHVS – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.04, Zacks reports.

Pharvaris Price Performance

Shares of Pharvaris stock traded down $0.33 during trading hours on Friday, hitting $33.50. The company’s stock had a trading volume of 94,663 shares, compared to its average volume of 452,426. Pharvaris has a 12 month low of $23.01 and a 12 month high of $43.25. The stock has a 50 day moving average of $33.29 and a 200 day moving average of $31.29. The company has a market capitalization of $2.19 billion, a PE ratio of -10.99 and a beta of -2.48.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on PHVS shares. Wall Street Zen cut shares of Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Royal Bank Of Canada upped their price target on Pharvaris from $52.00 to $62.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Oppenheimer reiterated an “outperform” rating on shares of Pharvaris in a research report on Friday, October 23rd. New Street Research set a $60.00 price objective on Pharvaris in a research report on Friday, August 14th. Finally, Wells Fargo & Company raised their price objective on Pharvaris from $55.00 to $65.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 9th. Fourteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $59.53.

Check Out Our Latest Analysis on PHVS

Insider Buying and Selling at Pharvaris

In other news, insider Wim Souverijns sold 20,000 shares of Pharvaris stock in a transaction on Monday, September 14th. The stock was sold at an average price of $39.31, for a total transaction of $786,200.00. Following the completion of the sale, the insider owned 45,111 shares of the company’s stock, valued at approximately $1,773,313.41. This trade represents a 30.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Johannes Gerardus Chri Schikan sold 200,000 shares of the business’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $35.00, for a total transaction of $7,000,000.00. Following the completion of the sale, the director directly owned 115,167 shares of the company’s stock, valued at approximately $4,030,845. The trade was a 63.46% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 510,810 shares of company stock worth $18,563,973 over the last three months. Company insiders own 11.84% of the company’s stock.

Pharvaris Company Profile

(Get Free Report)

Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing oral treatments for hereditary angioedema (HAE) and other conditions involving bradykinin-mediated swelling. The company was founded in 2015 and is based in Leiden, the Netherlands. Its lead candidate, deucrictibant, is an oral small-molecule antagonist of the bradykinin B2 receptor. Pharvaris is studying the candidate in different formulations for both on-demand treatment of HAE attacks and prevention of attacks.

See Also

Earnings History for Pharvaris (NASDAQ:PHVS)

Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.